Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.16483 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
Invest New Drugs
December 2024
Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myeloma (MM). The objective of this analysis was to characterize the exposure-efficacy and exposure-safety relationships of venetoclax when combined with carfilzomib and dexamethasone (VenKd) in t(11;14)-positive relapsed or refractory (R/R) MM patients from a phase 2 study. Fifty-seven patients receiving VenKd or Kd were included in the analysis.
View Article and Find Full Text PDFProteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
J Hematol Oncol
September 2024
Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120, Heidelberg, Germany.
Background: Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the extended time for generation of patient specific CAR T cells. Allogeneic NK cell therapy is a promising alternative, but strategies to enhance efficacy and persistence may be necessary.
View Article and Find Full Text PDFUse of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
J Oncol Pharm Pract
April 2024
Internal Medicine, HSHS St Mary's Hospital, Decatur, IL, USA.
Background: The plasma cell malignancy, multiple myeloma (MM), remains incurable despite advanced treatment protocols. Overexpression of Bcl-2 (an anti-apoptotic protein), in MM harboring the translocation (11;14), contributes to resistance to prior therapy. Venetoclax, a selective oral inhibitor of BCL-2 is a novel agent that shows promise as a therapeutic agent.
View Article and Find Full Text PDFEffective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Pathol Oncol Res
December 2023
Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) translocation remains less investigated. In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation.
View Article and Find Full Text PDFEvaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma.
Transl Oncol
November 2023
Invicro, a Konica Minolta Company, 119 4th Ave, Needham Heights, MA 02494, USA. Electronic address:
Background: FDG PET/CT is a tool for assessing response to therapy in various cancers, and may provide an earlier biomarker of clinical response. We developed a novel semi-automated approach for analyzing FDG PET/CT images in patients with multiple myeloma (MM) to standardize FDG PET application.
Methods: Patients (n = 8) with relapsed/refractory MM from the Phase 2 study (NCT02899052) of venetoclax plus carfilzomib and dexamethasone underwent FDG PET/CT at baseline and up to two timepoints during treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!